The funding will support clinical validation and preparations for CE marking of the company’s blood-based test for early detection of pancreatic cancer, it states.

“This marks an important milestone as we move from development to validation,” says CEO, Anna Brodén. “Our test has the potential to revolutionize both diagnostics and care for pancreatic cancer. We are pleased that our investors share our long-term vision.”